BioNexus Gene Lab Corp Common stock (BGLC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in BioNexus Gene Lab Corp Common stock, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

BioNexus Gene Lab Corp Common stock (BGLC) has returned -45.81% so far this year and -9.45% over the past 12 months.

Based on dividend-adjusted daily data since Sep 16, 2020, BGLC's average daily return is +1.20%, while the average monthly return is +2.11%. At this rate, your investment would double in approximately 2.8 years.

Historically, 37% of months were positive and 63% were negative. The best month was Sep 2020 with a return of +265.9%, while the worst month was Oct 2023 at -51.8%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 7 months.

On a daily basis, BGLC closed higher 29% of trading days. The best single day was Sep 17, 2020 with a return of +509.8%, while the worst single day was Sep 18, 2020 at -60.0%.

BioNexus Gene Lab Corp Common stock has an annualized alpha of 1993.76%, beta of -0.21, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 17, 2020.

• This stock participated in 168.55% of S&P 500 Index downside but only -53.23% of its upside — more exposed to losses than it benefited from rallies.
• Beta of -0.21 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

BGLC ranks 56 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for BioNexus Gene Lab Corp Common stock (BGLC) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the BioNexus Gene Lab Corp Common stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the BioNexus Gene Lab Corp Common stock was 99.41%, occurring on Feb 10, 2026. The portfolio has not yet recovered.

The current BioNexus Gene Lab Corp Common stock drawdown is 99.35%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of BioNexus Gene Lab Corp Common stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how BioNexus Gene Lab Corp Common stock is priced in the market compared to other companies in the Specialty Chemicals industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.